ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / HELP / earnings
COLL (59) ANNX (30) ARDX (24) AVBP (29) ⌘ Pro Terminal →

Helus Pharma Inc. (HELP) Next Earnings Date & Expected ±12.5% Move

$8.80 -16.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.51

Helus Pharma Inc. (HELP) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $774.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HELP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HELP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Helus Pharma Inc. (NASDAQ: HELP) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $8.80 (-16.94% 1D, market cap $774.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, HELP ranks #234 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HELP compare to COLL and ANNX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HELP carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, COLL (Collegium Pharmaceutical Inc.) holds a C- grade (59/100 RQD, P/E 12.4x, ROIC 85.0%, cap $774.8M) and ANNX (Annexon Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $767.8M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HELP?
▼

For Helus Pharma Inc. (HELP), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #234 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $8.51 (-3.24%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510053
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C-
Cash (12)Whales (8)SEC (13)Macro (11)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-2.3% Base Target
$16 Bull$9 Base$7 Bear
📬 FREE HELP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HELP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (53/100 Composite)
🔍 WHY HELP SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)

SEC XBRL Trailing 12 Months: 0.5% FCF Margin ($21.7M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
61
Grade C$10.50+4.2% Next Q
Q2 (-2Q)
58
Grade C$10.94-3.8% Next Q
Q3 (-1Q)
56
Grade C$10.52-16.3% Next Q
Current
53
Grade D+$8.80-0.9% Hist 90D α
Trajectory: C (61) → D+ (53)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HELP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HELP currently carries a cautious 53/100 (D+) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.88) and Max Pain ($9.24) forces dealer call-delta covering toward $15.91.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HELP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HELP Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 53%NO 47%Trade / Inspect Odds →
NEXT EST. WINDOW: Upcoming Quarter (~28 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.10 Expected Swing
$7.70 (-12.5%)Spot $8.80$9.90 (+12.5%)
MODEL EARNINGS SETUP GAUGE

HELP Quantitative Pre-Earnings Setup: 53/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (53/100)Model Risk Weight (47/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HELP)

  • ✓Walkthrough of HELP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
HELP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +66.35%▼ SUPPORT BREAKDOWN
2026-11-03O $10.71H $10.71L $8.80C $8.80VOL 1.15M
SUP: $9.33SMA50: $11.88SMA200: $7.74
$15.95$12.64$9.34$6.04$2.73SUP $9.33$8.802026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HELP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HELP Butterfly Map → + Track HELP →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HELP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HELP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HELP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HELP)

Health Care Rank #234 of 1015 ⚔️ COLL vs HELP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HELP vs. COLL, ANNX, ARDX, AVBP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Helus Pharma Inc. (HELP) ranks #234 by composite RQD confidence (53/100, grade D+) and #385 by equity capitalization ($774.1M). Within this direct 5-issuer industry benchmark cohort, COLL leads on earnings valuation at 12.4x trailing P/E, while COLL leads on capital efficiency and profitability with 85.0% ROIC and 59.3% gross margin. COLL currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with HELP at 53/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
HELP ACTIVE
Helus Pharma Inc.
D+ 53/100 — — — -16.94% $774.1M Benchmark Subject
COLL
Collegium Pharmaceutical Inc.
C- 59/100 12.4x 59.3% 85.0% -0.50% $774.8M /coll-vs-help →
ANNX
Annexon Inc.
E 30/100 — — -35.0% -2.72% $767.8M /annx-vs-help →
ARDX
Ardelyx Inc.
E 24/100 — 90.3% -32.7% 0.00% $755.0M /ardx-vs-help →
AVBP
ArriVent BioPharma Inc.
E 29/100 — — -35.0% -10.22% $733.2M /avbp-vs-help →

2. HELP Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Helus Pharma Inc. (HELP) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $774.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. HELP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HELP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Helus Pharma Inc. (NASDAQ: HELP) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $8.80 (-16.94% 1D, market cap $774.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, HELP ranks #234 in composite RQD confidence.

How does HELP compare to COLL and ANNX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HELP carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, COLL (Collegium Pharmaceutical Inc.) holds a C- grade (59/100 RQD, P/E 12.4x, ROIC 85.0%, cap $774.8M) and ANNX (Annexon Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $767.8M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HELP?

For Helus Pharma Inc. (HELP), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #234 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HELP trading relative to its 50-day, 200-day, and 52-week technical levels?

HELP last traded at $8.80 (-16.94% on volume of 3,889,049 shares), positioning the stock -25.93% below its 50-day simple moving average ($11.88) and +13.70% above its 200-day simple moving average ($7.74). Across its 52-week range of $3.76 to $15.15, HELP sits at the 44.2% percentile with a 14-day RSI of 44.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.70 to $9.90).

Direct Sub-Reports: HELP RQD Cockpit HELP 12M Forecast HELP Earnings & Move HELP Dividends & DRIP HELP Insiders & 13F HELP Whale Options HELP Profit Sankey HELP News & Why
ROARABLE RATING BRIEF • RQD 53/100 (D+) ✓ SEC XBRL & RQD VERIFIED

HELP — Helus Pharma Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Helus Pharma Inc. (HELP) earns a live Roarable RQD composite score of 53/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $8.80 (-16.94% 1D, market capitalization $774.1M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Helus Pharma Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The company's product offerings, customer base, and revenue model are not described in the source data. The source references a clinical program, including an HLP003 Phase 3 readout, but the source does not describe how the company monetizes any product.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 53/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 8/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $3.76 – $15.15 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlation links cannot be identified from source data. The key 2nd-order item a prospective investor should monitor is the HLP003 Phase 3 readout referenced in the news section, since the news frames near-term price volatility around that event, but the source does not establish any supply-chain dependency on it.

  • Key Question #1: Can HELP sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $15.15 52-week high?
  • Key Question #3: How sensitive is HELP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

HELP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Helus Pharma Inc. (HELP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HELP Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HELP Bull vs. Bear Conversation Board — What's Your Call at $8.80?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HELP 🐻 33% BEARISH CONVICTION
1. Pick Your Side on HELP:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $12.40 (+17.0%)
📌 Pinned Debate

The Forensic Balance Sheet pillar scores 13 of 20 with an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and Debt/Equity of 0.5, th

The street is overcomplicating Helus Pharma Inc. (HELP). The Forensic Balance Sheet pillar scores 13 of 20 with an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and Debt/Equity of 0.5, the strongest support in the rating.. With an RQD score of 53/100 (D+) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $11.45.

VolSurface_Trader 🐂 BULL

@BearTrap_Alert Shorting a 8/20 institutional whale-flow stock at $10.60 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $8.48 (-20.0%)
Spot @ $10.60

With ROIC at 0% and FCF yield at 0%, the Fundamental Cash Engine pillar scores only 12 of 20, and all margins are 0%.

With ROIC at 0% and FCF yield at 0%, the Fundamental Cash Engine pillar scores only 12 of 20, and all margins are 0%.. Look at the math on HELP: paying current EV/EBITDA multiples for 0.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $9.33 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%